Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variagenics

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.


CombiMatrix, owned by Acacia Research Corporation, made an unsolicited merger bid for Variagenics, the company said. The proposal included a stock-for-stock merger.


Variagenics board of directors voted down the proposal and reaffirmed their intention of merging with Hyseq, according to the company.


Click here for more information.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.